Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2010 / Cilt: 16 - Sayı: 1

Polikistik over sendromlu hastalarda c-erb-B2’nin immünohistokimyasal analizi ile premenopozal endometrium kanseri riskinin belirlenmesi

Determining the risk of premenopausal endometrial carcinoma by analysing expression of c-erb-B2 in patients with polycystic ovary syndrome

Pages
45–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In women with endometrial cancer, although no significant difference is found, lower mean age of PCO (+) patients preoccupies the possibility of developing cancer at early ages in PCOS. c-erb-B2 overexpression is not found in the endometrial tissues from women with PCOS and is therefore not a determining factor for endometrial cancer among these women.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The present study aims to determine the risk of premenopausal endometrial carcinoma by analyzing c-erb-B2 overexpression in patients with polycystic ovary syndrome (PCOS).
📊
Key Findings & Data:STUDY DESIGN: A total of 20 women with PCOS, 20 premenopausal women under the age of 50 with endometrial carcinoma and 20 healthy women were eligible for the study.
💡
Conclusion & Impact:In women with endometrial cancer, although no significant difference is found, lower mean age of PCO (+) patients preoccupies the possibility of developing cancer at early ages in PCOS. c-erb-B2 overexpression is not found in the endometrial tissues from women with PCOS and is therefore not a determining factor for endometrial cancer among these women.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The present study aims to determine the risk of premenopausal endometrial carcinoma by analyzing c-erb-B2 overexpression in patients with polycystic ovary syndrome (PCOS). STUDY DESIGN: A total of 20 women with PCOS, 20 premenopausal women under the age of 50 with endometrial carcinoma and 20 healthy women were eligible for the study. RESULTS: 18 (90%) of the endometrial cancers were endometrioid adenocarcinoma. C-erb-B2 overexpression, was found in 4 (20%) of endometrial cancer cases. Women with endometrial cancer were found to have significantly higher c-erb-B2 overexpression compared to women with PCOS and with normal endometrial biopsy (p=0.037). Polycystic ovaries (PCO), as a marker of PCOS, were investigated histologically from 10 of the 20 (50%) women with endometrial cancer. Comparing women with endometrial cancer on their own in terms of c-erb-B2 expression, no significant difference was found in PCO existence (p>0.05), and in terms of PCO existence, there was no significant difference in c-erb-B2 expression and age however, PCO (+) women were slightly younger than PCO (-) ones. All of the PCO (+) women had obesity, as compared to PCO (-) ones (p=0.005). CONCLUSION: C-erb-B2 overexpression appears to play a role in endometrial carcinomas. In women with endometrial cancer, although no significant difference is found, lower mean age of PCO (+) patients preoccupies the possibility of developing cancer at early ages in PCOS. c-erb-B2 overexpression is not found in the endometrial tissues from women with PCOS and is therefore not a determining factor for endometrial cancer among these women.

Özet

AMAÇ: Bu çalışmada polikistik over sendromu (PCOS) hastalarında premenopozal endometriyum kanseri riskinin c-erb- B2’nin immünohistokimyasal analizi ile belirlenmesi amaçlandı. GEREÇ VE YÖNTEM: Çalışma için 20 tane polikistik over sendromu olan hasta, 20 tane 50 yaşından küçük premenopozal endometriyum kanseri olan hasta ve 20 tane de sağlıklı kadın seçildi. Sağlıklı kadınlardan ve PCOS olan hastalardan pipel biyopsi ile endometrial biyopsi alındı. Endometrial biyopsi materyallerinde ve endometriyum kanseri olan hastaların histerektomi materyallerinde immünohistokimyasal olarak c-erb-B2 analizi yapıldı. BULGULAR: Endometriyum kanseri vakalarının %90’ı (18/20) endometrioid adenokarsinom idi. Bu hastalardan 4 tanesinde (%20) c-erb-B2 overekspresyonu izlendi. Endometriyum kanseri hastalarında c-erb-B2 overekspresyonu, PCOS’lu hastalara ve sağlıklı kadınlara göre anlamlı olarak yüksek bulundu (p=0.037). Endometriyum kanseri olan 20 hastanın 10’unda (%50) histolojik olarak, PCOS belirteci olan, polikistik overler (PCO) izlendi. Endometriyum kanseri hastalarını kendi içinde, c-erb-B2 overekspresyonu gösterenler ve göstermeyenler olarak grupladığımızda, histolojik PCO varlığı açısından anlamlı fark bulunmadı (p>0.05). Yine endometriyum kanseri hastalarını kendi içinde, histolojik PCO olanlar ve olmayanlar olarak grupladığımızda, c-erb-B2 ekspresyonu ve yaş bakımından anlamlı fark bulunmamakla birlikte, PCO(+) hastaların PCO(-) hastalara göre yaş ortalaması biraz daha düşüktü (sırasıyla 43.5±7 ve 46±2.9 ). PCO(+) hastalarda obesite oranı, PCO(-) olanlara göre anlamlı olarak yüksekti (p=0.005). SONUÇ: c-erb-B2 overekspresyonu endometriyum patogenezinde önemli rol oynamaktadır. Her ne kadar istatistiksel olarak anlamlı fark bulunmasa da; endometriyum kanserli hastalarda PCO (+) olan hastaların yaş ortalamasının, PCO(-) olanlara göre daha düşük olması, PCOS’lu hastalarda daha erken yaşlarda endometriyum kanseri gelişebileceğini düşündürmektedir. c-erb-B2 overekspresyonu PCOS’lu hastaların endometriyal dokularında tespit edilememiştir, dolayısıyla bu hastalarda premenopozal endometriyum kanseri için belirleyici bir faktör olmadığı sonucuna ulaşılmıştır.

🔖

Cite This Article

ARMAN, F., GÜNGÖR, T., ŞİRVAN, A. L., ALTINKAYA, S. Ö., MAT, B., HELVACIOĞLU, Y., BİLGE, Ü., MOLLLAMAHMUTOĞLU, L. (2010). Polikistik over sendromlu hastalarda c-erb-B2’nin immünohistokimyasal analizi ile premenopozal endometrium kanseri riskinin belirlenmesi. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 16 - Sayı: 1, 45–50. https://ajindex.com/articles/227007

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24 (29): 4783-91
  2. Prat J, Gallardo A, Cuatrecasas M, Catasus L. Endometrial carcinoma: pathology and genetics. Pathology 2007;39 (1):72-87
  3. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006;16(5):1897-902
  4. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 2005;99(2):388- 92
  5. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Gynecol Oncol 2005;105(3):575-80
  6. Giudice LC. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 2006;20(2):235-44
  7. Dunaif A, Givens JR, Haseltine FP, Merriam GR. Current issues in endocrinology and metabolism: polycystic ovary syndrome Boston: Blackwell;1992. p.377-84
  8. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(January(1)):19-25
  9. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70(2):209-62
  10. Gao JS, Shen K, Lang JH, Huang HF, Pan LY, Wu M, Jin Y, Chen QH. Clinical analysis of endometrial carcinoma patients aged 45 years and younger. Zhonghua Fu Chan Ke Za Zhi 2004;39(3):159-61
  11. Niwa K, Imai A, Hashimoto M, Yokoyama Y, MoriH, Matsuda Y, Tamaya T. A case control study of uterine endometrial cancer of pre- and post-menopausal women. Oncol Rep 2000;7(1):89-93
  12. Mariani A, Sebo TJ, Katzmann JA, Riehle DL, Dowdy SC, Keeney GL, Lesnick TG, Podratz KC. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res. 2005;25(4):2921-7
  13. Czerwenka K, Lu Y, Heuss F. Amplification and the expression of the c-erb-B2 oncogene in normal, hyperplastic, and malignant endometria. Int J Gynecol Pathol 1995;14(2):98-106
  14. Brys M, Semczuk A, Rechberger T, Krajewska WM. Expression of erb-B1 and erb-B2 genes in normal and pathological endometrium. O